Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.

MLA

Donadel, Camila D., et al. “Safety and Efficacy of a New Academic CD19-Directed CAR-T Cell for Refractory/Relapsed Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia in Brazil.” Bone Marrow Transplantation, vol. 59, no. 7, July 2024, pp. 1040–42. EBSCOhost, https://doi.org/10.1038/s41409-024-02283-6.

APA

Donadel, C. D., De Santis, G. C., Gonçalves, T. E., Pires, B. G., Palma, L. C., Gava, F., Guerino-Cunha, R. L., Faria, J. T. B., Silva, G. V. A., Darrigo-Junior, L. G., Fatobene, G., Rocha, V., Covas, D. T., Calado, R. T., & Clé, D. V. (2024). Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil. Bone Marrow Transplantation, 59(7), 1040–1042. https://doi.org/10.1038/s41409-024-02283-6

Chicago

Donadel, Camila D, Gil C De Santis, Thiago E Gonçalves, Bruno G Pires, Leonardo C Palma, Flavia Gava, Renato Luiz Guerino-Cunha, et al. 2024. “Safety and Efficacy of a New Academic CD19-Directed CAR-T Cell for Refractory/Relapsed Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia in Brazil.” Bone Marrow Transplantation 59 (7): 1040–42. doi:10.1038/s41409-024-02283-6.